ArticleTranslational psychiatry2022
Increased retention of tau PET ligand [
Article in Translational psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Neuroimaging Findings of Psychosis in Alzheimer's Disease: A Systematic Review.Brain and behavior · 2025Pooled it
- Blood-Based Biomarkers Predict Differential Longitudinal Decline in Alzheimer's Disease Psychosis: Evidence from Two Cohorts.medRxiv : the preprint server for health sciences · 2026Article
- Tau protein: Physiological functions and multifaceted roles in neurodegenerative and psychiatric disorders.Genomic psychiatry : advancing science from genes to society · 2025Article
- Clinical trials for neuropsychiatric syndromes in major and mild neurocognitive disorders: A CONSORT-based approach.International psychogeriatrics · 2025Review
- Recommendations for management and future investigation of psychosis in neurodegenerative disease: Findings from the International Psychogeriatric Association (IPA) working group.International psychogeriatrics · 2025Review
- Patterns of pathological tau deposition reflect the dynamics of cortical brain activity.Cell reports · 2025Article
- Tau Imaging: Use and Implementation in New Diagnostic and Therapeutic Paradigms for Alzheimer's Disease.Geriatrics (Basel, Switzerland) · 2025Review
- Emerging Pharmacological Approaches for Psychosis and Agitation in Alzheimer's Disease.CNS drugs · 2025Review
- An artificial intelligence-derived metabolic network predicts psychosis in Alzheimer's disease.Brain communications · 2025Article
- Association of psychosis with cognitive impairment is mediated by amyloidopathy in cognitive impairment.Frontiers in aging neuroscience · 2025Article
- Prognostic model for predicting Alzheimer's disease conversion using functional connectome manifolds.Alzheimer's research & therapy · 2024Article
- Psychosis in Alzheimer's disease is associated with specific changes in brain MRI volume, cognition and neuropathology.Neurobiology of aging · 2024Article
- The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- The Impact of Muscarinic Antagonism on Psychosis-Relevant Behaviors and Striatal [Biomedicines · 2023Article
- Imaging of Tauopathies with PET Ligands: State of the Art and Future Outlook.Diagnostics (Basel, Switzerland) · 2023Review
- Biomarker Candidates for Alzheimer's Disease Unraveled through In Silico Differential Gene Expression Analysis.Diagnostics (Basel, Switzerland) · 2022Article
- Hallucinations and delusions are associated with elevated tau PET signal independent of age, clinical severity, and amyloid burden.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Psychosis in Alzheimer's disease (AD) represents a distinct disease subtype with a more rapid progression of illness evidenced by an increased velocity of cognitive decline and a hastened mortality. Previous biomarker and post-mortem studies have implicated tau neuropathology as a possible mediator of the accelerated decline in AD psychosis. Tau positron emission tomography (PET) neuroimaging provides the opportunity to evaluate tau pathology in-vivo, so that clinical symptomatology can be correlated with disease pathology. [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.